Mizuho analyst Bradley Bowers raised the firm’s price target on Guardant Health (GH) to $100 from $75 and keeps an Outperform rating on the shares. The company reported a “broad-based” Q3 sales beat. The strong Q3 performance puts Guardant on an early trajectory towards achieving its 2028 targets, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $85 from $70 at Barclays
- Guardant Health price target raised to $100 from $75 at Canaccord
- Guardant Health Reports Strong Q3 2025 Growth
- Guardant Health: Strong Performance and Growth Potential Drive Buy Rating
- Closing Bell Movers: Meta sinks, Alphabet jumps after earnings